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SHORT COMMUNICATION
Beta-1 integrins mediate tumour cell adhesion to quiescent endothelial cells
in vitro
EA Price', DR Coombe2 and JC Murray'
'University ofNottingham Laboratory ofMolecular Oncology, CRC Department ofClinical Oncology, City Hospital, Nottingham,
NG5 IPB, UK; 2TVW Telethon Institute for Child Health Research, PO Box 855, West Perth, WA 6872, Australia.
Summary Metastatic spread of some solid tumours is thought to depend upon the adhesion of tumour cells to
the vascular endothelium followed by extravasation into surrounding tissues. We investigated the role of ,B1
integrins in the adhesion of the breast adenocarcinoma cell line MDA-MB-231 and the melanoma cell line
RPMI-7951 to quiescent human umbilical vein endothelial cells (HUVEC) in vitro. In the course of adhesion
assays, tumour cells were observed to adhere to quiescent HUVEC monolayers, particularly at endothelial
cell-cell junctions. Immunohistochemistry revealed concentration of ,B1 integrin expression at these sites.
Adhesion was reduced by pretreatment of either tumour cells or HUVEC with antibodies against ,B1 integrins.
Simultaneous treatment of HUVECs and tumour cells with these antibodies produced an additive blocking
effect, consistent with a heterotypic adhesion mechanism. Our data suggest that tumour cell and endothelial ,B1
integrins may play a crucial role in the arrest and migration of tumour cells through the vascular endothelium
in the absence of endothelial 'activation'.
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The interaction of tumour cells with endothelial cells lining
the microvasculature is an important step in the metastatic
cascade. A variety of endothelial and tumour adhesion
molecules have been implicated in this process, and much
attention has focused on the role of the integrin family of
receptors (Honn and Tang, 1992). These transmembrane
glycoproteins are composed of two non-covalently associated
subunits termed a and fi. There are at least 14 a-subunits
(150-200 kDa) and eight P-subunits (90-210 kDa). The cx-
subunits can associate with more than one type of f-unit,
leading to a wide range of integrin dimers (Hynes, 1992;
Albelda and Buck, 1990). Ligand binding is dependent upon
divalent cations (Gailit and Ruoslahti, 1988). The ligand
recognised by integrins depends upon the particular cc- and ,B-
subunits within the complex, and requires both subunits
(Buck et al., 1986). Endothelial integrins are involved in
adhesion to extracellular matrix (ECM) molecules and in
maintaining the integrity of the monolayer. Endothelial cells
express f,l, f3 and fl5 chains. The #1 integrins, which are
expressed on a wide range of cell types, dimerise with acs 1-6
and thereby mediate cellular adhesion to laminin, collagen
and fibronectin (Dejana, 1993). Integrins are also expressed
on a variety of tumour cells, and changes in their expression
may play a role in malignant progression and metastasis
(Albelda, 1993; Juliano and Varner, 1993).
In addition to mediating adhesion to extracellular matrix
components, beta-l integrins have also been reported to play
a role in tumour cell-endothelial cell adhesion. Lauri et al.
(1991) found that a5cfl expressed by tumour cell lines
mediated their adhesion to interleukin 1 (IL-1)-activated
human umbilical vein endothelial cells (HUVEC); treatment
of different tumour cell lines with polyclonal antiserum
against a5cB1 abrogated the enhanced adhesion. Some doubt
surrounds the physiological significance of adhesion of
tumour cells to endothelial cells activated by inflammatory
cytokines, as this leads to acute up-regulation of a number of
potential adhesion pathways. We have investigated the
expression of f1 integrins on two potentially metastatic
tumour cell lines and non-activated endothelial cell mono-
layers, and their role in mediating cell-cell adhesion.
Materials and methods
Cells and cell culture
The MDA-MB-231 human breast adenocarcinoma cell line
and the RPMI-7951 human melanoma line (American Tissue
Type Culture Collection, Rockville, MD, USA) were used in
all experiments. HUVEC were isolated and cultured
according to the method of Jaffe et al. (1973). Confluent
cultures of HUVECs were used at passage 3.
Tumour cell/endothelial cell adhesion assay
Tumour cell adhesion was measured as previously described
(Price et al., 1995). Briefly, HUVEC were grown on 96-well
gelatin-coated plates until confluent. Subconfluent tumour
cells were suspended with 10 mM EDTA (pH 7.0) and
incubated in this solution for 1 h at 37°C. The released
tumour cells were washed three times in Medium 199
supplemented with 0.1% bovine serum albumin (BSA)
(assay medium) and then fluorescence labelled by incubation
in 40 ,ug ml-' carboxy-fluorescein diacetate (CFDA; Sigma)
in the same medium for 30 min at 37°C. After three washes
in assay medium, cells were resuspended to give
1 x 106 cells ml-', and 50 p1 of cell suspension was added to
each well of washed HUVEC monolayers. The plates were
incubated for 30 min at 37°C to allow adhesion before
washing the wells three times with phosphate-buffered saline
(PBS). The cellular contents of each well were dissolved with
sodium dodecylsulphate (50 pl per well, 0.2%; Sigma, Poole,
UK) to release the fluorescent marker. Lysates were collected
and combined with two further washings with 50 pl of PBS/
A. Fluorescence of the cell lysates was determined with a
Fluoroskan II plate reader (Labsystems, Basingstoke, UK)
using a 485 nm excitation filter and a 538 nm emission filter.
Relative adhesion was calculated as follows:
Relative adhesion =
Fluorescence of sample
Fluorescence of untreated cells attached to untreated HUVEC
Data are expressed as the mean+s.e.m. of at least three
experiments performed in quadruplicate. Statistical analysis
of the significance of observed differences between groups
was carried out using Student's t test.
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Treatment with blocking antibodies
A rat monoclonal antibody recognising fll integrins was
obtained from Becton Dickinson (anti-CD29, clone 13).
Mouse anti-human VCAM-1 (clone l.G1 IBI) and mouse
anti-human VLA-4 (CDw49d, clone HP2/1 which recognises
the a4 integrin) were obtained from Serotec (Kidlington,
Oxford, UK). Tumour cells were detached from the culture
flasks with 10 mm EDTA, and washed twice before
incubation with antibodies. Cells (5 x 106) were incubated in
200 ,ul of antibody solution (10 ,ug ml-') for 30 min at 4°C.
After antibody treatment, cells were washed, resuspended to
a working dilution of 8 x 106 ml-' and used in adhesion
assays. To treat HUVEC with antibody, wells containing
monolayers were incubated with 50 p1 of antibody
(10 jug ml-l) for 30 min at room temperature.
Flow cytometry
Before primary antibody binding, cells were incubated in
0.25 ml of 2% normal goat serum (NGS, Sigma) for 20 min
at 4°C to block non-specific interactions with the secondary
antibody. Suspended tumour cells (5 x 106) were then
incubated in 150 ,l of primary antibody solution
(10 ,ug ml-') for 45 min at 4°C. This was followed by
incubation in 200 ,l of appropriate FITC-conjugated
secondary antibody (1: 50) for 30 min at 4°C. After
staining, cells were fixed in 1.5 ml of 4% paraformaldehyde
(BDH, Derby, UK). Control samples were incubated with
PBS/A in place of primary antibody. A Becton Dickinson
FACScan was used to analyse antibody binding.
Immunohistochemistry of HUVEC
Staining was performed on fixed, non-permeabilised mono-
layers of HUVEC grown to confluence on glass tissue culture
slides (Nunc, Naperville, IL, USA). Cells were washed with
PBS/A and fixed in 0.05% glutaraldehyde for 30 min at 37°C.
Monolayers were incubated with a 1 :9 solution of normal
goat serum in PBS/A for 25 min at room temperature to
block non-specific binding of the secondary antibody.
Monoclonal rat anti-CD29 (#I integrin) was used at
10 jug ml-' for 75 min at 4°C. The secondary antibody was
a FITC-conjugated goat anti-rat monoclonal (Sigma), used at
a 1: 50 dilution. Cells were incubated with secondary
antibody for 30 min at 4°C. Slides were mounted with a
1:1 solution of glycerol (Sigma) and PBS/A, and viewed with
an Optiphot microscope equipped with epifluorescence
(Nikon, Melville, NY, USA).
Silver staining of HUVEC
HUVECs were grown to confluence in 24-well dishes
precoated with rat tail tendon collagen, which was allowed
to gel (Boehringer Mannheim, Germany). Gels were formed
according to the manufacturer's instructions. Adhesion assays
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Figure 1 Fluorescence histograms demonstrating the expression of ,B1 integrins (MAb 13) and VLA-4 (CDw49d, MAbHP2/1) by
MDA-MB-231 and RPMI-7951 tumour cells obtained by flow cytometry. Control profiles (open curves) were obtained by omitting
primary antibodies. (a) MDA-MD-231 + anti-/Il integrin (b) RPMI-7951 +anti-/il integrin. (c) MDA-MB-231 +anti-VLA-4. (d)
RPMI-7951 +anti-VLA-4.
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were carried out using tumour cells disaggregated with
10 mM EDTA. After allowing the tumour cells to adhere to
HUVEC monolayers for 30 min, the wells were washed three
times, fixed with 0.1% glutaraldehyde in PBS/A and the
cultures stained with silver nitrate as described by Furie et al.
(1984).
Results
FACScan analysis demonstrated high levels of cell surface
expression of ,B1 integrins on both tumour cell lines (Figure
1). However, only the RPMI-7951 line expressed the a4,B1
integrin VLA-4, which is the ligand for VCAM-1 on
activated endothelial cells (Rice and Bevilacqua, 1989).
Immunofluorescence staining of intact HUVEC monolayers
confirmed the expression of,1 integrins by endothelial cells;
staining was particularly intense at endothelial cell-cell
junctions (Figure 2).
We previously demonstrated that both MDA-MB-231 and
RPMI-7951 tumour cells adhere to monolayers of quiescent
HUVEC in preference to gelatin, in the absence of cytokine
activation (Price et al., 1995). Under these conditions,
differential adhesion to HUVEC was maximal after 30 min,
when 40%+3% (n= 12) of MDA-MB-231 and 47%+2%
(n = 12) of RPMI-7951 tumour cells are adherent to HUVEC
monolayers. Consequently, all measurements were made after
30 min of incubation and adhesion data are hereafter
expressed as per cent control adhesion at 30 min.
We observed that blocking of cell-surface /1 integrins, by
preincubation of either HUVECs or tumour cells with anti-
CD29 (MAb 13), caused significant reductions in adhesion
(Figure 3). When both HUVECs and tumour cells were
pretreated simultaneously with antibody, the overall reduc-
tion in adhesion obtained was approximately equal to the
sum of the separate changes. Although RPMI-7951 cells
express the ,B1 integrin VLA-4 (see Figure 1), blocking
tumour cells with MAb HP2/1 or HUVEC with
MAb l.GlIBI against VCAM-1 (the endothelial receptor
for VLA-4) did not reduce the adhesion of RPMI-7951 cells
to HUVEC (data not shown). This suggests that the adhesion
of the RPMI-7951 cell line to the quiescent HUVEC is not
mediated by tumour cell-surface VLA-4 interacting with
VCAM-1 on HUVECs, and that alternative ,B1 integrins are
involved. MDA-MB-231 cells do not express VLA-4.
During the course of the adhesion experiments we
observed that, when incubated with HUVEC monolayers,
tumour cells tended to accumulate and adhere preferentially
at endothelial cell-cell junctions. To confirm this observa-
tion, we made a silver-stained preparation of MDA-MB-231
cells incubated with HUVEC for 30 min. This staining
technique highlights glycosaminoglycans present at the
cell-cell junctions, giving a 'paving stone' effect. Tumour
cells can be clearly seen lining up along cell junctions and are
rarely observed adhering to cell surfaces remote from such
junctions (Figure 4).
110
a
c;r
-
a:
-a
0=
100
90
80
70
60
50
*
MLA-MB-23S1 IrMI-7951I
Figure 3 The effects of pretreating MDA-MB-231 or RPMI-
7951 tumour cells with anti-#I integrin (MAb 13) on adhesion to
quiescent monolayers of HUVECs; L, adhesion of untreated
tumour cells to untreated HUVECs. L=1, HUVECs treated with
antibody; M, tumour cells treated with antibody; , HUVEC
and tumour cells treated with antibody. *P<0.05, n = 12.
Figure 2 Immunofluorescent staining of confluent HUVEC with
anti-/il integrin MAb 13. (a) Positive staining showing enrichment
of ,B1 integrins at endothelial cell-cell junctions. (b) Control with
primary antibody omitted (magnification x 400).
Figure 4 Localisation of tumour cells to endothelial cell-cell
junctions in a monolayer of human umbilical vein endothelial
cells. MDA-MB-231 cells were allowed to attach as described in
Materials and methods. Endothelial cell-cell junctions are silver
stained; cells are counterstained with Wright-Giemsa. Arrows
indicate examples of tumour cells clearly associated with
endothelial cell-cell junctions (magnification x 200).
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Discussion
Beta-I integrins are expressed at high levels on the surface of
both the MDA-MB-231 and the RPMI-7951 cell lines. In
addition, we found that these integrins are expressed by
HUVEC, on which they tend to be concentrated at cell-cell
junctions, as shown by Lampugnani et al. (1991). We also
observed that the tumour cells tend to localise at such sites
during adhesion assays. Beta-I integrins on both cell types
appear to function as adhesion molecules in our model, as
blocking these integrins on either the tumour cells or
HUVECs led to significant reductions in adhesion. This
adhesion is not based upon a homotypic interaction, as
simultaneous blocking of integrins on both tumour cell lines
and HUVECs produced an additive effect, which suggests a
heterotypic interaction between these cells.
Beta-I integrin expression on endothelial cells has
previously been demonstrated (Lampugnani et al., 1991).
They are also expressed on normal breast epithelium, on their
neoplastic counterparts at reduced levels (Mechtersheimer et
al., 1993), and on melanoma cells (Elices and Hemmler,
1989). Recently Maemura et al. (1995), while studying a2#1
expression using a range of normal and malignantly
transformed breast epithelial cell lines, showed that this
integrin is universally expressed but that its function as a
receptor for laminin is altered in a manner which appears to
be correlated with metastatic potential. Therefore, while
highly metastatic breast cell lines such as the MDA-MB-231
line (used in this study) express this integrin, its affinity for
laminin is reduced. This suggests that not tumour cell a2fll
but rather some other /1 integrin may be involved in
adhesion to endothelial cells in our model. Alternatively, a
ligand other than laminin on the endothelium is involved.
Many integrins are capable of interacting with multiple
ligands (Hynes, 1992); indeed, the ligand recognised by an
integrin may depend upon which cell type it is expressed on
(Elices and Hemler, 1989). Nor is there any reason to assume
that while /1 integrins on both tumour and endothelial cells
are involved in adhesion they interact with the same ligands
on either cell. As stated earlier, f1 integrins mediate the
adhesion of cells to extracellular matrix proteins; the integrin
a5fl1, for example, mediates adhesion to fibronectin.
However, MDA-MB-231 cells shed much of their newly
synthesised fibronectin into the culture medium (Incardona et
al., 1993), discounting fibronectin as the tumour ligand for
endothelial integrins. Lauri et al. (1991) found that
endothelial fibronectin was not involved in the ,B1 integrin-
mediated adhesion of various tumour cell lines to HUVEC.
Other extracellular matrix molecules such as epiligrin (Carter
et al., 1991) and collagen (Wayner and Carter, 1987) cannot
be ruled out as potential ligands in this model. Laminin may
also be a ligand (D'Ardenne et al., 1991), although possibly
for B1 integrins other than a2flL as discussed above.
Bliss et al. (1995) recently reported the inhibition of
adhesion of two breast cancer cell lines to endothelial cells by
antibodies against the a6fll integrin (a laminin receptor) in
one case and a5,B1 (a fibronectin receptor) in another. These
authors concluded that tumour cells interact with 'luminal
components of the extracellular matrix' and not directly with
the endothelial cell surface. These findings offer a potential
explanation for our observations on the localisation of
tumour cells to endothelial cell-cell junctions.
Another potential ligand for the /1 integrins, expressed on
both tumour and endothelial cells, is thrombospondin (TSP)
(Bornstein, 1995). MDA-MB-231 cells synthesise TSP and
express high-affinity TSP receptors (Incardona et al., 1993);
our preliminary data show that the RPMI-7951 cell line also
expresses TSP (data not shown). Additionally, HUVEC
express both TSP receptors and TSP clusters on the apical
surface, which mediate the adhesion of MCF-7 breast
adenocarcinoma cells (Incardona et al., 1995).
We may surmise that the unidentified endothelial ligand,
like the ,B1 integrins, must be expressed predominantly at
intercellular junctions. The transmembrane glycoprotein
CD31 (PECAM-1), which is highly enriched in endothelial
junctions, may play a role. CD31 participates in heterophilic
interactions with proteoglycans (Muller et al., 1992), and it
has been postulated to play a role in tumour cell adhesion
and migration through blood vessel walls (Honn and Tang,
1992; Tang et al., 1993). CD31 does not interact in a ligand/
counterligand manner with P1 integrins; however CD31
expressed on T-cell subsets has been shown to act as a
preferential amplifier of ,B1 integrin-mediated adhesion to
endothelial cells (Tanaka et al., 1992). This suggests that the
presence of CD31 at the endothelial cell-cell junction would
tend to favour integrin-based interactions, preferentially
amplifying the activity of /31 integrins at this site.
We conclude that ,B1 integrins expressed at endothelial
cell-cell junctions and on the surface of the MDA-MB-231
and RPMI-7951 tumour cell lines mediate heterotypic
adhesion. The ligands remain obscure. Putting these
observations into a physiological context, the model suggests
that such interactions localise tumour cells to sites where they
may more readily initiate the process of extravasation from
the vasculature through the blood vessel wall and into the
extravascular space. Furthermore, such a mechanism is more
physiologically relevant in that it is dependent upon
constitutively expressed molecules and not upon prior
'activation' of endothelial cells.
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